A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis

Genzyme, a Sanofi Company

Overview

This clinical study is to evaluate the safety and efficacy of Synvisc in patients with symptomatic shoulder osteoarthritis (OA). Patients will be given Synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the 3 month follow up period.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Osteoarthritis Musculoskeletal Diseases

Interventions

Synvisc (hylan G-F 20)DEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with symptomatic OA pain of shoulder (gleno-humeral) Exclusion Criteria: * Patients with current or prior conditions or treatment that would impede measurement of efficacy or safety

Locations (6)

Hopital Ambroise Pare

Boulogne-Billancourt, France

Clinique Saint Anne Lumiere

Lyon, France

Centre de Medecine et Traumatologie du Sport Clinique du Sport

Mérignac, France

CHRU Hopital Trousseau

Tours, France

Outcomes

Primary Outcomes

Pain relief

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.